- Home
- PCN vs CERT Comparison
PCN vs CERT Comparison
Compare PCN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCN | CERT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.7M | 860.9M |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCN | CERT |
|---|---|---|
| Price | $11.70 | $5.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 293.9K | ★ 3.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $11.40 | $4.45 |
| 52 Week High | $13.49 | $13.88 |
Technical Indicators
Market Signals| Indicator | PCN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 44.91 |
| Support Level | $11.40 | $5.19 |
| Resistance Level | $12.15 | $6.47 |
| Average True Range (ATR) | 0.10 | 0.35 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 33.61 | 39.65 |
Price Performance
Historical ComparisonAbout PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.